Skip to main content
RHHBF logo

Roche Holding AG (RHHBF) Stock Price & Analysis

Roche Holding AG (RHHBF) — price $485.00 (+1.16%), as of the Nov 19, 2026 trading session; market cap $386B.

Educational signal · not a buy or sell recommendation · How to read this

$485.00 +$5.58 (+1.16%) Market Cap $386B

Roche Holding AG · RHHBF · Healthcare · Drug Manufacturers - General

Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MRK · Merck & Co., Inc. · 69 /100
  • ABBV · AbbVie Inc. · 83 /100
  • AMGN · Amgen Inc. · 84 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$485.00
Change on the day+1.16%
52-week range$375.00–$514.08
Market capitalisation$386B—
Price / earnings (trailing)26.45
Shares traded on the day1
Beta (volatility vs the S&P 500)0.35

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $316, high $501, latest $485. $501 $316 high $501 Oct 17, 2025 Nov 19, 2026 · $485 $372Oct 17, 2025$316Oct 31, 2025$378Nov 14, 2025$395Nov 28, 2025$405Dec 12, 2025$407Dec 26, 2025$414Jan 9, 2026$425Jan 23, 2026$450Feb 6, 2026$484Feb 20, 2026$465Mar 6, 2026$376Mar 20, 2026$416Apr 2, 2026$416Apr 17, 2026$406May 1, 2026$423May 15, 2026$420May 29, 2026$420Jun 12, 2026$418Jun 26, 2026$430Jul 10, 2026$438Jul 24, 2026$442Aug 7, 2026$468Aug 21, 2026$441Sep 4, 2026$445Sep 18, 2026$420Oct 2, 2026$458Oct 16, 2026$501Oct 30, 2026$480Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Roche Holding AG (RHHBF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Negative
Debt/Equity Weak
ROE Strong
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Roche Holding AG (RHHBF), and what does it report?

Short answer

Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Healthcare / Drug Manufacturers General Headquarters: Grenzacherstrasse 124, Basel, BS, 4070, CH. It employs 103,249 people and is led by Thomas Schinecker. In Q2 FY2026 it reported revenue of CHF 30.19B and net income of CHF 6.83B. The market values it at $386B.

2 · Latest results

What do the latest results show for Roche Holding AG (RHHBF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 30.19B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 30.19BCHF 6.83BCHF 8.44 (diluted)
Q4 FY2025CHF 30.59BCHF 5.47BCHF 11.43 (diluted)
Q2 FY2025CHF 15.92BCHF 3.71BCHF 4.62 (diluted)
Q4 FY2024CHF 31.64BCHF 2.02BCHF 2.52 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Roche Holding AG (RHHBF)?

Short answer · as of

The distress and quality screens read Altman Z 5.31 · Piotroski F 6. Trailing ratios: ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 3.7% · free-cash-flow yield 5.2%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RHHBF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RHHBF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Roche Holding AG (RHHBF)?

Read these with our analysis →

RHHBF Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the RHHBF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is RHHBF a good stock to buy?

Stock Expert AI does not rate RHHBF buy, sell or hold. Roche Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RHHBF stock price today?

The last price recorded for Roche Holding AG (RHHBF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Roche Holding AG do?

Roche Holding AG is a global healthcare company based in Switzerland, operating in two primary divisions: pharmaceuticals and diagnostics. In its pharmaceutical segment, Roche develops and markets a wide range of therapies for serious medical conditions including cancer, neurological disorders, infectious diseases, and immunological conditions.

What are the key factors to evaluate for RHHBF?

Evaluate RHHBF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does RHHBF data refresh on this page?

RHHBF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RHHBF's recent stock price performance?

Roche Holding AG (RHHBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model across pharmaceuticals and diagnostics provides revenue stability. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RHHBF overvalued or undervalued right now?

The trailing P/E of Roche Holding AG (RHHBF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research RHHBF before investing?

Before investing in Roche Holding AG (RHHBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.